- Home
- LSPD vs NVAX Comparison
LSPD vs NVAX Comparison
Compare LSPD & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSPD
- NVAX
- Stock Information
- Founded
- LSPD 2005
- NVAX 1987
- Country
- LSPD Canada
- NVAX United States
- Employees
- LSPD N/A
- NVAX N/A
- Industry
- LSPD
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LSPD
- NVAX Health Care
- Exchange
- LSPD Nasdaq
- NVAX Nasdaq
- Market Cap
- LSPD 2.5B
- NVAX 2.0B
- IPO Year
- LSPD 2020
- NVAX 1995
- Fundamental
- Price
- LSPD $15.13
- NVAX $9.76
- Analyst Decision
- LSPD Buy
- NVAX Buy
- Analyst Count
- LSPD 14
- NVAX 6
- Target Price
- LSPD $18.46
- NVAX $17.83
- AVG Volume (30 Days)
- LSPD 476.3K
- NVAX 7.2M
- Earning Date
- LSPD 11-07-2024
- NVAX 11-07-2024
- Dividend Yield
- LSPD N/A
- NVAX N/A
- EPS Growth
- LSPD N/A
- NVAX N/A
- EPS
- LSPD N/A
- NVAX N/A
- Revenue
- LSPD $966,275,000.00
- NVAX $987,667,000.00
- Revenue This Year
- LSPD $24.83
- NVAX N/A
- Revenue Next Year
- LSPD $17.62
- NVAX N/A
- P/E Ratio
- LSPD N/A
- NVAX N/A
- Revenue Growth
- LSPD 26.19
- NVAX N/A
- 52 Week Low
- LSPD $11.01
- NVAX $3.53
- 52 Week High
- LSPD $21.71
- NVAX $23.86
- Technical
- Relative Strength Index (RSI)
- LSPD 46.02
- NVAX 36.20
- Support Level
- LSPD $14.77
- NVAX $9.52
- Resistance Level
- LSPD $15.92
- NVAX $10.63
- Average True Range (ATR)
- LSPD 0.32
- NVAX 0.57
- MACD
- LSPD -0.20
- NVAX -0.12
- Stochastic Oscillator
- LSPD 16.67
- NVAX 9.97
About LSPD Lightspeed Commerce Inc. Subordinate Voting Shares
Lightspeed Commerce Inc provides an omni-channel commerce-enabling SaaS platform. Its software platform provides customers with the functionality it needs to engage with consumers, manage their operations, accept payments, and grow their businesses. The company sells its platform through a direct sales force in the United States, Canada, New Zealand, United Kingdom, Australia, Germany, and other countries. It derives a majority of its revenue from the United States.
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.